XBiotech with potential breakthrough for treatment of HS with MABp1, study suggests

Texas-headquartered biosciences company XBiotech announced Monday the publication of data from its randomized phase 2 study in which it tested its True Human antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS).

The results have been published online as an article in press in the peer-reviewed Journal of Investigative Dermatology in a manuscript titled, “MABp1 Targeting Interleukin-1alpha for Moderate to Severe Hidradenitis Suppurativa not Eligible for Adalimumab: A Randomized Study.” The article is planned to be featured in an upcoming print issue of the journal.

Prof. Evangelos Giamarellos-Bourboulis, who supervises the department at Attikon University Hospital in Greece where the featured study was conducted and and was the Principal Investigator of the study said that the study demonstrates its mechanism of action, pointing out that it is „truly unique for a candidate drug treatment for HS“.

He said that MABp1 represents a potential breakthrough in the treatment of HS as it could cover an overtly unmet need for patients either failing or not eligible for adalimumab. As he pointed out, adalimumab is the only registered biological treatment of HS to date. „Data acquired by this study shed light to the promising efficacy of MABp1 even for naïve patients,” he said.